The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial

L. Dirven, M.J. van den Bent, A. Bottomley, N. van der Meer, B. van der Holt, M.J. Vos, A.M.E. Walenkamp, L.V. Beerepoot, M.C.J. Hanse, J.C. Reijneveld, A. Otten, F.Y.F.L. de Vos, M. Smits, J.E.C. Bromberg, W. Taal, M.J.B. Taphoorn

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1321-1330
JournalEuropean Journal of Cancer
Issue number10
Publication statusPublished - 2015

Cite this